Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies

Roberto Iacovelli, Filippo Pietrantonio, Alessio Farcomeni, Claudia Maggi, Antonella Palazzo, Francesca Ricchini, Filippo De Braud, Maria Di Bartolomeo

Research output: Contribution to journalArticle

Abstract

Chemotherapy is a cornerstone in treatments of gastric cancer, but despite its benefit, less than 60% of patients receive salvage therapy in clinical practice. We performed a systematic review and meta-analysis based on trial data on the role of second-line treatment of advanced gastric cancer. MEDLINE/PubMed and Cochrane Library were searched for randomized phase III trials that compared active therapy to best supportive care in advanced gastric cancer. Data extraction was conducted according to the PRISMA statement. Summary HR for OS was calculated using a hierarchical Bayesian model and subgroup analysis was performed based on baseline Eastern Cooperative Oncology Group Performance Status (ECOG) performance status (0 vs. 1 or more). A total of 1,407 patients were evaluable for efficacy, 908 were treated in the experimental arms, with chemotherapy (231 pts) or with targeted therapies (677 pts). The risk of death was decreased by 18% (HR = 0.82; 95% CI, 0.79-0.85; posterior probability HR≥1:

Original languageEnglish
Article number0108940
JournalPLoS One
Volume9
Issue number9
DOIs
Publication statusPublished - Sep 30 2014

Fingerprint

Chemotherapy
stomach neoplasms
systematic review
meta-analysis
drug therapy
Stomach Neoplasms
Meta-Analysis
Drug Therapy
Salvaging
therapeutics
Oncology
Salvage Therapy
cooperatives
Therapeutics
PubMed
MEDLINE
death
Libraries

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. / Iacovelli, Roberto; Pietrantonio, Filippo; Farcomeni, Alessio; Maggi, Claudia; Palazzo, Antonella; Ricchini, Francesca; De Braud, Filippo; Di Bartolomeo, Maria.

In: PLoS One, Vol. 9, No. 9, 0108940, 30.09.2014.

Research output: Contribution to journalArticle

@article{b48a954bcca247e48c4ac90fde306eef,
title = "Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies",
abstract = "Chemotherapy is a cornerstone in treatments of gastric cancer, but despite its benefit, less than 60{\%} of patients receive salvage therapy in clinical practice. We performed a systematic review and meta-analysis based on trial data on the role of second-line treatment of advanced gastric cancer. MEDLINE/PubMed and Cochrane Library were searched for randomized phase III trials that compared active therapy to best supportive care in advanced gastric cancer. Data extraction was conducted according to the PRISMA statement. Summary HR for OS was calculated using a hierarchical Bayesian model and subgroup analysis was performed based on baseline Eastern Cooperative Oncology Group Performance Status (ECOG) performance status (0 vs. 1 or more). A total of 1,407 patients were evaluable for efficacy, 908 were treated in the experimental arms, with chemotherapy (231 pts) or with targeted therapies (677 pts). The risk of death was decreased by 18{\%} (HR = 0.82; 95{\%} CI, 0.79-0.85; posterior probability HR≥1:",
author = "Roberto Iacovelli and Filippo Pietrantonio and Alessio Farcomeni and Claudia Maggi and Antonella Palazzo and Francesca Ricchini and {De Braud}, Filippo and {Di Bartolomeo}, Maria",
year = "2014",
month = "9",
day = "30",
doi = "10.1371/journal.pone.0108940",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies

AU - Iacovelli, Roberto

AU - Pietrantonio, Filippo

AU - Farcomeni, Alessio

AU - Maggi, Claudia

AU - Palazzo, Antonella

AU - Ricchini, Francesca

AU - De Braud, Filippo

AU - Di Bartolomeo, Maria

PY - 2014/9/30

Y1 - 2014/9/30

N2 - Chemotherapy is a cornerstone in treatments of gastric cancer, but despite its benefit, less than 60% of patients receive salvage therapy in clinical practice. We performed a systematic review and meta-analysis based on trial data on the role of second-line treatment of advanced gastric cancer. MEDLINE/PubMed and Cochrane Library were searched for randomized phase III trials that compared active therapy to best supportive care in advanced gastric cancer. Data extraction was conducted according to the PRISMA statement. Summary HR for OS was calculated using a hierarchical Bayesian model and subgroup analysis was performed based on baseline Eastern Cooperative Oncology Group Performance Status (ECOG) performance status (0 vs. 1 or more). A total of 1,407 patients were evaluable for efficacy, 908 were treated in the experimental arms, with chemotherapy (231 pts) or with targeted therapies (677 pts). The risk of death was decreased by 18% (HR = 0.82; 95% CI, 0.79-0.85; posterior probability HR≥1:

AB - Chemotherapy is a cornerstone in treatments of gastric cancer, but despite its benefit, less than 60% of patients receive salvage therapy in clinical practice. We performed a systematic review and meta-analysis based on trial data on the role of second-line treatment of advanced gastric cancer. MEDLINE/PubMed and Cochrane Library were searched for randomized phase III trials that compared active therapy to best supportive care in advanced gastric cancer. Data extraction was conducted according to the PRISMA statement. Summary HR for OS was calculated using a hierarchical Bayesian model and subgroup analysis was performed based on baseline Eastern Cooperative Oncology Group Performance Status (ECOG) performance status (0 vs. 1 or more). A total of 1,407 patients were evaluable for efficacy, 908 were treated in the experimental arms, with chemotherapy (231 pts) or with targeted therapies (677 pts). The risk of death was decreased by 18% (HR = 0.82; 95% CI, 0.79-0.85; posterior probability HR≥1:

UR - http://www.scopus.com/inward/record.url?scp=84907486352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907486352&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0108940

DO - 10.1371/journal.pone.0108940

M3 - Article

C2 - 25268988

AN - SCOPUS:84907486352

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 9

M1 - 0108940

ER -